PATENT CLAIM ANALYSIS

Application Number: 16039813
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "006900"]

Abstract:
The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of α4β7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.

Claim (Index 42):
The method of  claim 34 , wherein the peptide molecule or pharmaceutically acceptable salt thereof or pharmaceutical composition is provided as an initial does followed by one or more subsequent doses, and the minimum interval between any two doses is a period of less than 1 day, and wherein each of the doses comprises an effective amount of the peptide molecule or pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 95.0
- Lexical Diversity: 1.03704
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14714198', '15514983', '15614047', '14050349', '14872975']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.9081590605572712
- 35 USC 102 Novelty (BERT): 0.6569275877867573
- Combined Prediction Score: 0.8830359132802199
- Mean Citation Score: 845.1664359999999
- Max Citation Score: 1016.0851
- Similarity Product: 623.0428007787408

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test